{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ANAB",
  "name": "AnaptysBio, Inc.",
  "url": "https://frontierpicks.com/dossiers/ANAB/",
  "json_url": "https://frontierpicks.com/dossiers/ANAB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The dateless wait acquired a docket: a 2026-07-28 stipulation set post-trial briefing to an Oct 20 Chancery argument, and ANAB has rebuilt from ~$54 (Jul 24) to $58.47 (Aug 14) on no company news. The written opinion deciding Jemperli reversion still has no date — the schedule gives the wait structure, not resolution.",
  "invalidation_trigger": "A weekly close below $52 breaks the base built off the 2026-07-24 trough near $54 and reads as the market pricing an adverse ruling; secondarily, the 2026-10-20 post-trial argument passing with the written opinion still unscheduled returns the equity to dateless drift.",
  "catalyst_date": "2026-08-21",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Post-2026-04-20 structure is permanent: ANAB is a pure royalty book (Jemperli/GSK, imsidolimab/Vanda). The clinical pipeline and its cash went to First Tracks (Nasdaq: TRAX).",
    "The live legal event is a dateless written opinion. Chancery post-trial opinions can land weeks to months after the 2026-10-20 oral argument.",
    "On the split/dividend-adjusted series the 52-week high prints $69.81; unadjusted quotes elsewhere show a higher figure because of the April spin distribution.",
    "Jemperli royalty is tiered 8-25%, reaching 25% above $2.5B net sales — economics step up with GSK's sales, not with any action by Anaptys.",
    "No Anaptys Q2 2026 results release surfaced in the sources reviewed as of 2026-08-16; the Q1 2026 release was dated 2026-05-12.",
    "Second dated royalty trigger sits outside the litigation: Vanda's imsidolimab FDA action date is 2026-12-12 for generalized pustular psoriasis."
  ],
  "body_markdown": "## Current Thesis\nThe July trial produced no verdict, and for two weeks the equity was a wait with no timer. That changed on 2026-07-28, when Anaptys and the Tesaro/GSK defendants filed a Joint Stipulation and Proposed Order — approved by the Court — laying out post-trial briefing: opening brief 2026-08-21, answering brief 2026-09-25, reply 2026-10-09, and post-trial oral argument 2026-10-20. The equity has rebuilt with it, from a trough close near $54 on 2026-07-24 to $58.47 on 2026-08-14, RSI(14) 63.6, still 16.2% under the $69.81 adjusted 52-week high. What an investor is buying is a single-question royalty stub: whether a Delaware Vice Chancellor's written opinion returns Jemperli rights to Anaptys. The docket now gives that wait a shape through October; it does not give it a resolution date, because the opinion itself remains unscheduled.\n\n## Bull Case\n- **The wait acquired a calendar.** The 2026-07-28 stipulation converted an open-ended post-trial silence into four dated steps ending in oral argument on 2026-10-20. Between 2026-07-24 and 2026-08-14 the stock recovered roughly 8% against that schedule, with no company press release in the window to explain it.\n- **The royalty is compounding while the case runs.** Q1 2026 (released 2026-05-12): collaboration revenue $25.6M, Jemperli royalties $24.7M, up 44% year over year. The disputed asset is growing regardless of who ends up owning the economics.\n- **April's ruling narrowed the downside case.** The 2026-04-24 Chancery decision dismissed Tesaro's anticipatory-breach claim and rejected its royalty-reduction request; the stock rose ~12% on 2026-04-27. Anaptys's own reversion claims survived into the July trial, so the written opinion decides an upside question on top of a preserved rate.\n- **The burn left the building.** The First Tracks spin completed 2026-04-20. TRAX's Q2 2026 release (2026-08-12) reported $168.0M cash and investments at 2026-06-30, R&D of $25.6M for the quarter against $39.3M a year earlier, and runway into Q2 2028 — the clinical spending sits there, not at ANAB.\n- **A second dated royalty trigger exists.** Vanda's imsidolimab carries an FDA action date of 2026-12-12 for generalized pustular psoriasis, with Phase III data published in NEJM Evidence in late April 2026.\n\n## Bear Case\n- **Nothing resolves before late October, and probably not then.** The 2026-08-21 filing is a brief, not a decision. Post-trial argument is 2026-10-20 and the Vice Chancellor's written opinion has no scheduled date; Chancery opinions routinely follow argument by weeks to months.\n- **A bench ruling is not modellable.** An adverse opinion removes the reversion option and reopens the royalty-reduction path that April's order closed. No amount of analysis converts that into a distribution.\n- **The recovery is unexplained by news flow.** No Anaptys press release has surfaced after 2026-05-12 in the sources reviewed, and no Q2 2026 results release appeared as of 2026-08-16. The move off $54 is happening on a thin, undocumented bid.\n- **Sell-side dispersion is extreme.** Dated targets run UBS $60 (2026-04-21) and Barclays $63 (2026-04-22) against Leerink $85 (2026-04-28), Piper Sandler $93 (2026-05-04) and HC Wainwright $95 (2026-06-10). A $60-to-$95 band on the same asset is the market saying the litigation, not the royalty, sets the value.\n- **Single counterparty, single asset.** Value rides on GSK's execution of Jemperli. Any deprioritisation or label setback lands with nothing behind it, because the pipeline left with TRAX on 2026-04-20.\n\n## Setup & Price Structure\n- Reference close 2026-08-14: **$58.47**. 52-week high **$69.81** on the split/dividend-adjusted series (-16.2%); three-month return -7.4%; RSI(14) 63.6.\n- The July damage came in two gaps: into roughly $55.76 around 2026-07-14 as the trial opened, then a further ~13% drop on 2026-07-20, with the trough close near $54 on 2026-07-24. The base built off that low has held for three weeks and is what the current level sits on.\n- Rising RSI into the low-60s with price still one-sixth below the high describes a repair, not a breakout: the pre-trial shelf in the high-$60s has not been reclaimed.\n- **The narrative is maturing.** The narrative is well known and dated — covered since the 2026-04-24 ruling — and it is still working, with the stock up off the July trough. But flow is moderating: no company headline after 2026-05-12, no dated sell-side action after HC Wainwright on 2026-06-10, and no items in the 30-day news feed reviewed. That is a known situation held by a narrow base, not a fresh one attracting new attention.\n- **Crowding and positioning observables:** no retail-sentiment coverage cluster in the window reviewed; no analyst revision in roughly nine weeks; no insider transactions or equity issuance surfaced; no confirmed upcoming earnings date, since the Q2 2026 release has not appeared in the sources reviewed and Q1 came on 2026-05-12. The inference — stated as inference — is that the August bid is docket-driven rather than flow-driven, and thin bids reverse cheaply.\n\n## Catalyst Calendar (next 30 days)\n\n- Beyond the window, on the same schedule: **2026-09-25** defendants' answering brief; **2026-10-09** Anaptys reply brief; **2026-10-20** post-trial oral argument. The written opinion follows at the Court's discretion, with no announced date.\n- **2026-12-12** — FDA action date for Vanda's imsidolimab in generalized pustular psoriasis, the next royalty-adding event independent of the litigation.\n\n## Elapsed catalysts\n\n- **2026-08-21** — Anaptys opening post-trial brief due, Delaware Court of Chancery. The only dated event inside the window; the brief is a public docket item that shows how Anaptys frames the reversion claim after four days of testimony. *(passed 5d ago)*\n- Not dated: an Anaptys Q2 2026 results release, which had not surfaced in the sources reviewed as of 2026-08-16. *(passed 10d ago)*\n\n## What Would Change Our Mind\nThe structural break is the base that formed off the 2026-07-24 trough near $54 giving way — that base is the entire evidence that the docket schedule restored a bid. A weekly close below $52 removes it and reads as the market discounting an adverse opinion rather than waiting for one. Two non-price conditions do the same work: the 2026-10-20 post-trial argument coming and going with the written opinion still unscheduled into year-end, which returns the equity to the dateless drift that produced the July unwind; and any post-trial opinion denying reversion, which ends the thesis outright at whatever price it lands on. On the other side, a company disclosure that Jemperli royalties continued the Q1 trajectory — $24.7M, +44% year over year — would strengthen the annuity leg independent of the ruling.\n\n## Correlation Notes\n- ANAB does not trade with the biotech tape in any usable way; its two largest 2026 moves (+12% on 2026-04-27, ~-13% on 2026-07-20) were both Delaware docket events. Sector ETFs are a poor hedge and a poor read-through.\n- The closest live comparable is GSK's Jemperli disclosure: the royalty base is GSK product sales, so GSK quarterly oncology detail is the fundamental input that moves the asset's value while the ownership question is litigated.\n- TRAX is the spin sibling and shares nothing economically after 2026-04-20 — its 2026-08-12 Q2 print (cash $168.0M, runway into Q2 2028) tells a reader where the clinical risk went, and its price action carries no information about ANAB's royalty book.\n- Royalty-company peers (the cohort HC Wainwright convened at its 2026-05-06 royalty conference, which Anaptys's CEO attended) are the valuation frame the sell-side is using for the post-litigation state, not for the current one.",
  "first_seen": "2026-04-28",
  "last_analyzed": "2026-08-16T14:01:54+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}